Skip to main content
NASDAQ:VIR

Vir Biotechnology Competitors

$39.55
+0.44 (+1.13 %)
(As of 05/13/2021 12:00 AM ET)
Add
Compare
Today's Range
$38.31
$41.11
50-Day Range
$38.75
$52.70
52-Week Range
$25.31
$141.01
Volume416,235 shs
Average Volume1.53 million shs
Market Capitalization$5.14 billion
P/E RatioN/A
Dividend YieldN/A
Beta-0.99

Competitors

Vir Biotechnology (NASDAQ:VIR) Vs. TECH, ARGX, QGEN, RGEN, NVAX, and NBIX

Should you be buying VIR stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Vir Biotechnology, including Bio-Techne (TECH), argenx (ARGX), QIAGEN (QGEN), Repligen (RGEN), Novavax (NVAX), and Neurocrine Biosciences (NBIX).

Vir Biotechnology (NASDAQ:VIR) and Bio-Techne (NASDAQ:TECH) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, earnings, dividends, profitability, analyst recommendations, valuation and risk.

Analyst Ratings

This is a summary of current recommendations for Vir Biotechnology and Bio-Techne, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vir Biotechnology20502.43
Bio-Techne03702.70

Vir Biotechnology presently has a consensus target price of $66.00, suggesting a potential upside of 66.88%. Bio-Techne has a consensus target price of $396.1111, suggesting a potential downside of 0.14%. Given Vir Biotechnology's higher possible upside, research analysts plainly believe Vir Biotechnology is more favorable than Bio-Techne.

Valuation & Earnings

This table compares Vir Biotechnology and Bio-Techne's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vir Biotechnology$8.09 million635.73$-174,680,000.00($5.76)-6.87
Bio-Techne$738.69 million20.88$229.30 million$3.86102.76

Bio-Techne has higher revenue and earnings than Vir Biotechnology. Vir Biotechnology is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

54.5% of Vir Biotechnology shares are owned by institutional investors. Comparatively, 93.8% of Bio-Techne shares are owned by institutional investors. 37.2% of Vir Biotechnology shares are owned by insiders. Comparatively, 3.8% of Bio-Techne shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Vir Biotechnology and Bio-Techne's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vir Biotechnology-339.61%-47.11%-39.44%
Bio-Techne32.69%12.20%8.09%

Volatility & Risk

Vir Biotechnology has a beta of -0.99, suggesting that its share price is 199% less volatile than the S&P 500. Comparatively, Bio-Techne has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500.

Summary

Bio-Techne beats Vir Biotechnology on 11 of the 14 factors compared between the two stocks.

Vir Biotechnology (NASDAQ:VIR) and argenx (NASDAQ:ARGX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, earnings, dividends, profitability, analyst recommendations, valuation and risk.

Analyst Ratings

This is a summary of current recommendations for Vir Biotechnology and argenx, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vir Biotechnology20502.43
argenx071102.61

Vir Biotechnology presently has a consensus target price of $66.00, suggesting a potential upside of 66.88%. argenx has a consensus target price of $297.8750, suggesting a potential upside of 14.01%. Given Vir Biotechnology's higher possible upside, research analysts plainly believe Vir Biotechnology is more favorable than argenx.

Valuation & Earnings

This table compares Vir Biotechnology and argenx's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vir Biotechnology$8.09 million635.73$-174,680,000.00($5.76)-6.87
argenx$78.17 million171.49$-182,520,000.00($4.73)-55.24

Vir Biotechnology has higher earnings, but lower revenue than argenx. argenx is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

54.5% of Vir Biotechnology shares are owned by institutional investors. Comparatively, 54.2% of argenx shares are owned by institutional investors. 37.2% of Vir Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Vir Biotechnology and argenx's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vir Biotechnology-339.61%-47.11%-39.44%
argenxN/AN/AN/A

Volatility & Risk

Vir Biotechnology has a beta of -0.99, suggesting that its share price is 199% less volatile than the S&P 500. Comparatively, argenx has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500.

Summary

argenx beats Vir Biotechnology on 8 of the 14 factors compared between the two stocks.

Vir Biotechnology (NASDAQ:VIR) and QIAGEN (NYSE:QGEN) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, earnings, dividends, profitability, analyst recommendations, valuation and risk.

Analyst Ratings

This is a summary of current recommendations for Vir Biotechnology and QIAGEN, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vir Biotechnology20502.43
QIAGEN05902.64

Vir Biotechnology presently has a consensus target price of $66.00, suggesting a potential upside of 66.88%. QIAGEN has a consensus target price of $60.76, suggesting a potential upside of 30.67%. Given Vir Biotechnology's higher possible upside, research analysts plainly believe Vir Biotechnology is more favorable than QIAGEN.

Valuation & Earnings

This table compares Vir Biotechnology and QIAGEN's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vir Biotechnology$8.09 million635.73$-174,680,000.00($5.76)-6.87
QIAGEN$1.53 billion6.95$-41,460,000.00$1.4332.52

QIAGEN has higher revenue and earnings than Vir Biotechnology. Vir Biotechnology is trading at a lower price-to-earnings ratio than QIAGEN, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

54.5% of Vir Biotechnology shares are owned by institutional investors. Comparatively, 43.6% of QIAGEN shares are owned by institutional investors. 37.2% of Vir Biotechnology shares are owned by insiders. Comparatively, 9.0% of QIAGEN shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Vir Biotechnology and QIAGEN's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vir Biotechnology-339.61%-47.11%-39.44%
QIAGEN11.18%17.51%8.44%

Volatility & Risk

Vir Biotechnology has a beta of -0.99, suggesting that its share price is 199% less volatile than the S&P 500. Comparatively, QIAGEN has a beta of 0.41, suggesting that its share price is 59% less volatile than the S&P 500.

Summary

QIAGEN beats Vir Biotechnology on 10 of the 14 factors compared between the two stocks.

Vir Biotechnology (NASDAQ:VIR) and Repligen (NASDAQ:RGEN) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, earnings, dividends, profitability, analyst recommendations, valuation and risk.

Analyst Ratings

This is a summary of current recommendations for Vir Biotechnology and Repligen, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vir Biotechnology20502.43
Repligen00503.00

Vir Biotechnology presently has a consensus target price of $66.00, suggesting a potential upside of 66.88%. Repligen has a consensus target price of $222.75, suggesting a potential upside of 31.30%. Given Vir Biotechnology's higher possible upside, research analysts plainly believe Vir Biotechnology is more favorable than Repligen.

Valuation & Earnings

This table compares Vir Biotechnology and Repligen's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vir Biotechnology$8.09 million635.73$-174,680,000.00($5.76)-6.87
Repligen$270.24 million34.47$21.41 million$1.07158.55

Repligen has higher revenue and earnings than Vir Biotechnology. Vir Biotechnology is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

54.5% of Vir Biotechnology shares are owned by institutional investors. Comparatively, 84.3% of Repligen shares are owned by institutional investors. 37.2% of Vir Biotechnology shares are owned by insiders. Comparatively, 1.7% of Repligen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Vir Biotechnology and Repligen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vir Biotechnology-339.61%-47.11%-39.44%
Repligen13.40%6.58%5.00%

Volatility & Risk

Vir Biotechnology has a beta of -0.99, suggesting that its share price is 199% less volatile than the S&P 500. Comparatively, Repligen has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500.

Summary

Repligen beats Vir Biotechnology on 10 of the 13 factors compared between the two stocks.

Vir Biotechnology (NASDAQ:VIR) and Novavax (NASDAQ:NVAX) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, earnings, dividends, profitability, analyst recommendations, valuation and risk.

Analyst Ratings

This is a summary of current recommendations for Vir Biotechnology and Novavax, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vir Biotechnology20502.43
Novavax11402.50

Vir Biotechnology presently has a consensus target price of $66.00, suggesting a potential upside of 66.88%. Novavax has a consensus target price of $216.3333, suggesting a potential upside of 78.79%. Given Novavax's stronger consensus rating and higher possible upside, analysts plainly believe Novavax is more favorable than Vir Biotechnology.

Valuation & Earnings

This table compares Vir Biotechnology and Novavax's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vir Biotechnology$8.09 million635.73$-174,680,000.00($5.76)-6.87
Novavax$18.66 million480.46$-132,690,000.00($5.80)-20.86

Novavax has higher revenue and earnings than Vir Biotechnology. Novavax is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

54.5% of Vir Biotechnology shares are owned by institutional investors. Comparatively, 49.9% of Novavax shares are owned by institutional investors. 37.2% of Vir Biotechnology shares are owned by insiders. Comparatively, 3.3% of Novavax shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Vir Biotechnology and Novavax's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vir Biotechnology-339.61%-47.11%-39.44%
Novavax-133.10%-1,346.17%-45.85%

Volatility & Risk

Vir Biotechnology has a beta of -0.99, suggesting that its share price is 199% less volatile than the S&P 500. Comparatively, Novavax has a beta of 2.01, suggesting that its share price is 101% more volatile than the S&P 500.

Summary

Vir Biotechnology beats Novavax on 8 of the 14 factors compared between the two stocks.

Vir Biotechnology (NASDAQ:VIR) and Neurocrine Biosciences (NASDAQ:NBIX) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, earnings, dividends, profitability, analyst recommendations, valuation and risk.

Analyst Ratings

This is a summary of current recommendations for Vir Biotechnology and Neurocrine Biosciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vir Biotechnology20502.43
Neurocrine Biosciences071302.65

Vir Biotechnology presently has a consensus target price of $66.00, suggesting a potential upside of 66.88%. Neurocrine Biosciences has a consensus target price of $127.8333, suggesting a potential upside of 39.06%. Given Vir Biotechnology's higher possible upside, research analysts plainly believe Vir Biotechnology is more favorable than Neurocrine Biosciences.

Valuation & Earnings

This table compares Vir Biotechnology and Neurocrine Biosciences' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vir Biotechnology$8.09 million635.73$-174,680,000.00($5.76)-6.87
Neurocrine Biosciences$788.10 million11.03$37.01 million$0.39235.72

Neurocrine Biosciences has higher revenue and earnings than Vir Biotechnology. Vir Biotechnology is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

54.5% of Vir Biotechnology shares are owned by institutional investors. Comparatively, 95.3% of Neurocrine Biosciences shares are owned by institutional investors. 37.2% of Vir Biotechnology shares are owned by insiders. Comparatively, 4.3% of Neurocrine Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Vir Biotechnology and Neurocrine Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vir Biotechnology-339.61%-47.11%-39.44%
Neurocrine Biosciences8.96%18.18%9.50%

Volatility & Risk

Vir Biotechnology has a beta of -0.99, suggesting that its share price is 199% less volatile than the S&P 500. Comparatively, Neurocrine Biosciences has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500.

Summary

Neurocrine Biosciences beats Vir Biotechnology on 11 of the 14 factors compared between the two stocks.


Vir Biotechnology Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Bio-Techne logo
TECH
Bio-Techne
1.8$396.66+3.1%$15.43 billion$738.69 million63.47
argenx logo
ARGX
argenx
1.3$261.28+1.2%$13.41 billion$78.17 million-55.24Gap Up
QIAGEN logo
QGEN
QIAGEN
1.7$46.50+0.5%$10.60 billion$1.53 billion57.41
Repligen logo
RGEN
Repligen
1.9$169.65+1.1%$9.31 billion$270.24 million206.89Analyst Report
Novavax logo
NVAX
Novavax
1.8$121.00+5.6%$8.97 billion$18.66 million-23.18Earnings Announcement
Analyst Report
Analyst Revision
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$91.93+0.2%$8.69 billion$788.10 million98.85Analyst Report
Unusual Options Activity
CRISPR Therapeutics logo
CRSP
CRISPR Therapeutics
1.7$101.00+0.2%$7.65 billion$289.59 million-30.98Analyst Upgrade
Acceleron Pharma logo
XLRN
Acceleron Pharma
1.6$123.32+1.7%$7.49 billion$73.99 million-47.61
Fate Therapeutics logo
FATE
Fate Therapeutics
1.8$71.51+1.1%$6.72 billion$10.68 million-38.86
Denali Therapeutics logo
DNLI
Denali Therapeutics
1.5$51.70+1.0%$6.27 billion$26.68 million-23.39
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.7$41.77+1.7%$5.95 billion$195.99 million261.06Earnings Announcement
Analyst Downgrade
Insider Selling
Analyst Revision
News Coverage
China Biologic Products logo
CBPO
China Biologic Products
0.8$119.99+1.7%$4.72 billion$503.70 million33.52Upcoming Earnings
Adaptive Biotechnologies logo
ADPT
Adaptive Biotechnologies
1.6$33.62+2.1%$4.72 billion$85.07 million-35.39Analyst Report
Insider Selling
Twist Bioscience logo
TWST
Twist Bioscience
1.6$88.13+3.3%$4.31 billion$90.10 million-23.50Analyst Revision
Beam Therapeutics logo
BEAM
Beam Therapeutics
1.3$66.14+1.1%$4.14 billion$20,000.00-4.71Earnings Announcement
Analyst Report
Analyst Revision
Kodiak Sciences logo
KOD
Kodiak Sciences
1.7$80.32+1.1%$4.12 billionN/A-34.62Earnings Announcement
Analyst Upgrade
Analyst Revision
Iovance Biotherapeutics logo
IOVA
Iovance Biotherapeutics
1.9$25.01+4.3%$3.82 billionN/A-13.03Analyst Revision
Allogene Therapeutics logo
ALLO
Allogene Therapeutics
1.3$26.94+3.7%$3.81 billionN/A-12.65
SpringWorks Therapeutics logo
SWTX
SpringWorks Therapeutics
1.8$68.32+2.4%$3.35 billionN/A-39.26Analyst Downgrade
Relay Therapeutics logo
RLAY
Relay Therapeutics
1.8$27.50+0.4%$2.49 billionN/A0.00
Revolution Medicines logo
RVMD
Revolution Medicines
1.7$30.74+3.0%$2.26 billion$50.04 million0.00Earnings Announcement
Analyst Report
Analyst Revision
Vericel logo
VCEL
Vericel
1.1$47.86+1.4%$2.22 billion$117.85 million-4,786,000.00Analyst Report
Insider Selling
Gap Up
NanoString Technologies logo
NSTG
NanoString Technologies
1.7$48.42+7.0%$2.19 billion$125.57 million-28.32Earnings Announcement
Analyst Report
Gap Up
Editas Medicine logo
EDIT
Editas Medicine
1.6$31.40+1.0%$2.13 billion$20.53 million-18.05
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.5$11.96+4.4%$2.13 billion$48.83 million-15.74
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.7$23.55+1.3%$2.10 billionN/A-11.00Earnings Announcement
Analyst Upgrade
Analyst Revision
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
0.9$45.37+5.9%$2.04 billionN/A0.00
bluebird bio logo
BLUE
bluebird bio
1.8$29.31+1.8%$1.98 billion$44.67 million-2.67
Sorrento Therapeutics logo
SRNE
Sorrento Therapeutics
1.3$6.35+3.6%$1.82 billion$31.43 million-4.35Gap Up
Ocugen logo
OCGN
Ocugen
1.0$8.23+4.6%$1.63 billionN/A-5.56Earnings Announcement
Analyst Upgrade
Gap Up
Replimune Group logo
REPL
Replimune Group
1.5$34.69+3.9%$1.61 billionN/A-19.60
REGENXBIO logo
RGNX
REGENXBIO
1.6$35.29+1.4%$1.50 billion$35.23 million-14.23Analyst Upgrade
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$10.40+0.7%$1.50 billion$102.43 million-17.33Analyst Revision
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.4$34.06+2.9%$1.47 billionN/A0.00Earnings Announcement
Analyst Upgrade
News Coverage
AlloVir logo
ALVR
AlloVir
1.5$22.35+1.3%$1.46 billionN/A0.00Analyst Report
Immunovant logo
IMVT
Immunovant
1.6$14.61+7.0%$1.43 billionN/A-11.33Unusual Options Activity
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$62.54+0.3%$1.39 billionN/A-42.26Earnings Announcement
Analyst Downgrade
Analyst Revision
News Coverage
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.4$14.72+6.0%$1.24 billionN/A-3.19Analyst Report
News Coverage
Gap Up
Alector logo
ALEC
Alector
1.3$15.50+8.3%$1.24 billion$21.22 million-6.95
Translate Bio logo
TBIO
Translate Bio
1.6$16.35+2.3%$1.23 billion$7.80 million-15.28
Curis logo
CRIS
Curis
1.3$13.07+24.5%$1.20 billion$10 million-15.94Earnings Announcement
Analyst Report
Unusual Options Activity
News Coverage
Gap Down
Forma Therapeutics logo
FMTX
Forma Therapeutics
1.8$24.91+4.9%$1.18 billion$100.56 million0.00
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$13.89+0.3%$1.05 billion$356.07 million6.81Analyst Report
Cortexyme logo
CRTX
Cortexyme
1.3$34.33+6.5%$1.02 billionN/A-14.30Earnings Announcement
Insider Selling
Vaxcyte logo
PCVX
Vaxcyte
1.7$19.09+2.2%$980.37 millionN/A0.00Earnings Announcement
Scholar Rock logo
SRRK
Scholar Rock
1.5$28.45+0.5%$978.48 million$20.49 million-11.80Earnings Announcement
News Coverage
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$26.56+4.9%$960.46 millionN/A-4.39Earnings Announcement
Insider Selling
Analyst Revision
Mesoblast logo
MESO
Mesoblast
1.4$6.73+0.7%$873.14 million$32.16 million-7.65
Sutro Biopharma logo
STRO
Sutro Biopharma
1.5$18.83+7.9%$868.31 million$42.74 million-209.22Analyst Revision
News Coverage
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.5$22.61+0.0%$862.41 millionN/A0.00Earnings Announcement
Analyst Revision
This page was last updated on 5/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.